ABBV-075 | Smad Signal

Vulnerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors

Lloyd T. Lam*, Xiaoyu Lin, Emily J. Faivre, Ziping Yang, Xiaoli Huang, Denise M. Wilcox, Richard J. Bellin, Sha Jin, Stephen K. Tahir, Michael Mitten, Terry Magoc#, Anahita Bhathena, Warren M. Kati, Daniel H. Albert, Yu Shen, Tamar Uziel

Oncology Discovery, AbbVie, Inc.

1 North Waukegan Road, North Chicago, IL 60064-6098, USA.

#Former AbbVie Employee

Running title: Combination of BET and BCL2 inhibitors in SCLC

Key words: BET, BCL2, ABBV-075, ABT-199 / venetoclax, apoptosis, SCLC Abbreviations: SCLC, small cell lung cancer; BET, bromodomain and extra-terminal

Disclosure: All authors are employees of AbbVie. TM was an employee of AbbVie at the time of the study. The design, study conduct, and financial support for this research were provided by AbbVie. AbbVie participated in the interpretation of data, review, and approval of the manuscript.

*Correspondence: Lloyd T. Lam, AbbVie, Translational Oncology & Precision Medicine, bldg AP- 10, dept R4CD, AbbVie, 1 North Waukegan Road, North Chicago, IL 60064-6098, USA.

E-mail: [email protected]

Phone: 847-937-5585 Fax: 847-935-4994

Abstract

10% to 15% of all lung cancers are small cell lung cancer (SCLC). SCLC usually grows and metastasizes before it is diagnosed and relapses rapidly upon treatment. Unfortunately, no new targeted agent has been approved in the past 30 years for patients with SCLC. The BET (bromodomain and extra-terminal) proteins bind acetylated histones and recruit protein complexes to promote transcription initiation and elongation. BET proteins have been shown to regulate expression of key genes in oncogenesis such as MYC, CCND2, and BCL2L1. Here, we demonstrate that ~50% of SCLC cell lines are exquisitely sensitive to growth inhibition by the BET inhibitor, ABBV-075. The majority of these SCLC cell lines underwent apoptosis in response to ABBV-075 treatment via induction of caspase 3/7 activity. ABBV-075 enhanced the expression of proapoptotic protein BIM and down-regulated antiapoptotic proteins BCL2 and BCLxl to a lesser extent. Furthermore, BET inhibition increased BCL2-BIM complex, thus priming the cells for apoptosis. Indeed strong synergy was observed both in vitro and in vivo when co-treating the cells with BET inhibitor and the BH3-mimetic, BCL2 inhibitor venetoclax (ABT-199). ABBV-075 interaction with venetoclax positively correlated with BCL2 expression. Taken together, our studies provide a rationale for treating SCLC with BET and BCL2 inhibitors in tumors with high BCL2 protein expression.

Introduction

10% to 15% of all lung cancers are small cell lung cancer (SCLC), named for the size of the cancer cells when seen under a microscope and strongly correlated with smoking (1, 2). SCLC often starts in the bronchi near the center of the chest and usually grows and metastasizes rapidly before it is diagnosed. Although a good initial response to chemotherapy and
2

radiotherapy is achieved in most patients, almost all patients relapse within a year with resistant disease. Unfortunately, no new targeted treatment has been approved in the past 30 years for patients with SCLC (3).

Recent genome-wide characterization of SCLC identified a high frequency of genomic alterations linked to mutagen exposure in tobacco smoke. There are uniform recurrent mutations in SCLC that include loss of function of the tumor suppressors TP53 and RB1 in 75- 90% tumors (4). Loss of TP53 allows for genomic instability that leads to accumulation of further driver mutations such as MYC, MYCN, or MYCL amplification, and PTEN loss or mutations.
Upregulation of the anti-apoptotic proteins such as BCL2, BCLxl, and MCL1 were shown in SCLC cell lines and tumors (5, 6). These anti-apoptotic proteins bind pro-apoptotic BH3 domain proteins such as BIM and BAD and prevent cells from undergoing apoptosis (7).

Although multiple targeted agents are being tested in clinical trials, none of the agents are showing sustainable efficacy (3). There is increasing evidence that immune responses against SCLC cells make immunotherapy a viable therapeutic approach, but further understanding and testing is required (8). Given the unmet need in this indication, additional therapies that can extend survival are required. The BET (bromodomain and extra-terminal) proteins bind acetylated histones or transcription factors and recruit protein complexes to promote transcription initiation and elongation. There are four members in this family-BRD2, BRD3, BRD4 and BRDT that share a common structure of two N-terminal bromodomains that have high levels of sequence conservation as well as an extra-terminal (ET) domain and a more divergent C-terminal recruitment domain. In hematologic cancers, BET proteins have been shown to regulate expression of MYC and other oncogenic transcription factors that drive disease pathology (9). Pharmacologic inhibition of BET binding to acetylated proteins has been

shown to inhibit tumor growth in MYC-dependent cancers, such as leukemia (10, 11), multiple myeloma (9, 12), acute myeloid leukemia (AML) (13), aggressive B cell lymphoma such as Burkitt’s lymphoma (14), and neuroblastoma (15).

ABBV-075 is a potent inhibitor of all BRD family proteins (BRD2, BRD3, BRD4, and BRDT)(16-18), and currently being tested in a phase 1 clinical trial (ClinicalTrials.gov; NCT02391480). SCLC was shown to be sensitive to BET inhibition in pre-clinical models (19, 20); here we demonstrate that SCLC cell lines are sensitive to ABBV-075 and elucidate the potential mechanism of action. Approximately ~50% of SCLC cell lines are exquisitely sensitive to growth inhibition by the BET inhibitor ABBV-075, and many of them undergo BIM-mediated apoptosis. In addition, synergistic cell killing was observed when co-treating the cells with ABBV-075 and the BCL2 inhibitor, venetoclax (ABT-199) (21, 22), and activity correlated with BCL2 expression. This combination was also efficacious in SCLC xenograft models. Our results identify a novel therapeutic combination for SCLC, and support a viable rationale for additional testing of the potential benefit of venetoclax with BET inhibitors.

Materials and Methods Reagents

ABBV-075 (N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin- 4-yl)phenyl]ethanesulfonamide) (23) and venetoclax (ABT-199) were synthesized at AbbVie, Inc. (North Chicago, IL). All siRNAs (Control: 6568S; BCL2L11: 6461S; BAK: 6486S; BAX: 6321S; BAD:
6512S, and BCL2L1: 6362S) were purchased from Cell Signaling Technology (Beverly, MA).

Cells, cell culture, transfection, and cell-based assays

SCLC cell lines were obtained from American Type Culture Collection (ATCC, Manassas, VA) and The Leibniz Institute DSMZ – German Collection of Microorganisms and Cell Cultures (Braunschweig, Germany) between 2003 and 2006. The cells were tested for mycoplasma using MycoAlert Detection Kit (Lonza, Walkersville, MD), authenticated using GenePrint 10 STR Authentication Kit (Promega, Madison, WI) prior to performing experiments, and grown in media as recommended by the supplier.

siRNAs were introduced into the cells by reverse transfection using Lipofectamine RNAiMax according to manufacturer’s instructions (Invitrogen, Carlsbad, CA). Briefly, siRNAs were first mixed with Lipofectamine RNAiMax in Opti-MEM (Invitrogen) and dispensed in 96- well tissue culture plates. Cells were added at 1.5-2.5 X 10^4 cells/ 100 l to final concentration of 20 nM siRNA. The cells were then grown in medium with ABBV-075. Forty-eight hours after transfection, cells were assayed for viability.

Cell viability and caspase 3/7 activation were measured using CellTiter-Glo® or Caspase- Glo® 3/7 luminescentassays, respectively, according to the manufacturer’s protocol (Promega, Madison, WI). IC50 calculation was performed using GraphPad Prism software (La Jolla, CA).
Statistical analysis was carried out using Microsoft Excel to determine p value (2-tailed) and p<0.05 was indicated by * in the figures.

Caspase inhibitor Z-VAD-FMK purchased from MPBio (Santa Ana, CA) was pre-incubated with cells for 30 minutes before treatment with ABBV-075.

Flow cytometry analysis for cell cycle and apoptosis

Cells in logarithmic growing phase were treated with compounds for designated time. Cells were harvested and subjected to cell cycle or apoptosis analyses using PI/RNase Staining Buffer or Annexin V Apoptosis Detection Kit I, respectively, according to manufacturer’s
5

protocols (BD Pharmingen, San Diego, CA). All flow cytometry analyses were performed on FACSCalibur (BD Biosciences).

Combination studies

Combination studies were performed in 20 SCLC cell lines with increasing concentration of ABBV-075 and venetoclax. Synergistic activity of ABBV-075 and venetoclax was determined using the Bliss additivity model (24), whereby the combined response C of both agents with individual effects A and B is C = A + B – (A × B), where A and B represent the fractional inhibition between 0 and 1. Combined response scores greater than 600 were considered strongly synergistic; 400-600 were considered synergistic; 250-400 were considered additive; and 0-250 were considered no combination effect.

Western Blot Analysis

Cell lysates were prepared in cell lysis buffer (Cell Signaling Technology, Danvers, MA) with protease inhibitor cocktail (Roche, Indianapolis, IN). 30 μg of total protein was resolved on a 12% SDS polyacrylamide gel and probed with anti-MCL1 (Cell Signaling #94296), anti-BCLxl (Cell Signaling #2764), anti-BCL2 (Abcam Ab-32124), anti-BIM (Cell Signaling # 2933) and anti- actin (Santa Cruz Biotechnology, Santa Cruz, CA).

RNA expression assays

All reagents for RT-qPCR were obtained from Life Tech (Carlsbad, CA). RNA was harvested using the PureLink RNA mini kit. cDNA was generated with the High-Capacity cDNA Reverse Transcription (RT) kit. Quantitative PCR (qPCR) was performed with TaqMan Universal PCR master mix and pre-designed probes on a Quant Studio Flex6 (BCL2L1 Hs00236329_m1; BAX Hs00180269_m1; BAD Hs00188930_m1; BCL2 Hs00608023_m1; BCL2L11
6

Hs01076940_m1; BAK Hs00832876_g1). Relative gene expression was analyzed using the DDCt method.

QuantiGene assay was described previously (25), and performed according to the manufacture’s protocol (Affymetrix / eBioscience, Inc., San Diego, CA)

ELISA to measure BCL2-BIM complex

Enzyme-linked immunosorbent assay (ELISA) to detect BCL2-Bim complex was performed according to Phillips et al. (26).

In vivo studies

Female SCID Beige mice (Charles River, Wilmington, MA) were group-housed 8-10 per cage and weighed 21-22 grams at initiation of therapy. Food and water were available ad libitum throughout the studies. All experiments were conducted in compliance with AbbVie's Institutional Animal Care and Use Committee and the National Institutes of Health Guide for Care and Use of Laboratory Animals guidelines in a facility accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care.
To generate xenografts, a suspension of viable tumors cells mixed with Matrigel (phenol red free, BD Biosciences) in a ratio of 1:1 (V/V) were injected subcutaneously into the flank of 6- to 8-week-old mice (five million cells per site). Inoculated mice were randomization into groups and treatment initiated when mean tumor volume was approximately 200 mm3. Tumor growth was assessed by measuring tumor size with calipers and calculating volume using the formula (L
× W2/2; L=length, W=width). Inhibition of tumor growth was assessed at the time the vehicle- treated group was terminated by calculating the ratio of the mean volume of the test drug

group to the mean volume of the vehicle-treated (control) group (T/C) and calculating percent inhibition of control ((1-T/C) × 100).

Results

SCLC cell lines undergo apoptosis upon BET inhibitor (ABBV-075) treatment

We first investigated the sensitivity of twenty-four SCLC cell lines to the BET inhibitor, ABBV-075. ABBV-075 demonstrated strong growth inhibition of half of the SCLC cell lines (Fig. 1A) as defined by IC50 values ≤0.1 μM. In addition, the BET inhibitor induced apoptosis in half of the SCLC cell lines tested, as determined by ≥40% positive Annexin V staining (Fig. 1B). There was a significant correlation (R2=0.59) between apoptosis and anti-proliferative activity (Fig. 1C).

We next investigated the cellular response to ABBV-075 to better understand the sensitivity of SCLC cell lines. Caspases are proteases that “execute” apoptosis. To determine whether caspase 3/7 are involved in the BET inhibitor activity, we treated multiple SCLC cell lines with increasing concentration of ABBV-075. SCLC cell lines (NCI-H211, NCI-H146, H1963, and H69) that are more sensitive to ABBV-075 showed strong activation of caspase 3/7 while less sensitive cell lines (NCI-H1048 and H345) did not show caspase activation (Fig. 1D). The activation of caspase 3/7 was abrogated with pre-incubation of NCI-H211, NCI-H146 and H1963 cells with pan-caspase inhibitor prior to treatment with ABBV-075 (Supplemental Fig.
1). Together, these data suggest that inhibition of BET family proteins could be an effective treatment for SCLC tumors and that apoptosis could be induced by ABBV-075 in SCLC cell lines. We also noted that some SCLC lines were sensitive to the anti-proliferative effects of ABBV-075 without evidence of apoptosis (Fig. 1B). Since BET inhibitor is known to inhibit cell cycle at the

G1 phase, we tested whether non-apoptotic cell lines underwent cell cycle arrest. Indeed, NCI- H1048 cells showed increase in G1 arrest and decreased S phase (Fig. 1E). Our data indicate that BET inhibitor could assert its effect through apoptosis or cell cycle arrest.

Involvement of BIM in ABBV-075-mediated apoptosis

Given that apoptosis was observed in these cells, we reasoned that components of the intrinsic apoptotic pathway may be involved in the sensitivity to BET inhibitor. We first evaluated the role of pro-apoptotic proteins in mediating ABBV-075 induced-apoptosis by silencing the expression of pro-apoptotic proteins using siRNAs. siRNAs that rescued the cells from ABBV-075-induced apoptosis could serve to identify proteins that mediate this pathway. We focused on BIM and BAD as they were recently described to play a role in response to BET inhibitors (14, 27-30). BIM is an activator BH3-only protein that binds and inactivates all anti- apoptotic proteins and is essential for activation of BAX- and BAK-dependent cell death program (31). BAD is a sensitizer BH3-only protein that binds and inactivates BCL2 and BCLxl. BAX and BAK initiate apoptosis by forming a pore in the mitochondrial outer membrane that allows cytochrome c to be released into the cytoplasm and activate the caspase cascade. The silencing of these proteins would act as controls for preventing apoptosis. As shown in Fig. 2A, silencing BCL2L11 (encodes BIM), BAD, BAX and BAK led to a substantial or partial rescue from ABBV-075 induced apoptosis in H1963 or NCI-H146 cells, respectively. The level of silencing of these genes by siRNAs was shown in Suppl. Fig. 2.

An independent evaluation on the role of these proteins was performed by gene expression analysis of pro-apoptotic proteins (BCL2L11 that encodes BIM, BAD, BAX, and BAK) and anti-apoptotic proteins (BCL2 and BCL2L1 that encodes BCLxl) in NCI-H146 and H1963 cells upon treatment with ABBV-075. Expression of BCL2L11 was induced around 2-fold (Fig. 2B)
9

while expression of BCL2 and BCL2L1 was reduced in both NCI-H146 and H1963 cells (Suppl. Fig. 3A). No change in BAD, BAX, and BAK expression was observed (Fig. 2B). In addition, ABBV-075 treatment induced BIM protein expression (Fig. 2C) and moderately reduced BCL2 and BCLxL protein levels (Suppl. Fig. 3B and C). The increased expression of pro-apoptotic BCL2L11 (BIM) together with small reduction in anti-apoptotic BCLxl and BCL2 may tip the scales toward an apoptotic response to ABBV-075 in sensitive SCLC cell lines.

BCL2 as predictive biomarker for ABBV-075/ABT-199 combination in SCLC

BCL2 overexpression and gene amplification are common in SCLC (32). Our findings that ABBV-075 induces apoptosis and modulates the expression of BH3 protein led us to speculate whether apoptosis can be further augmented by combination with a specific BCL2 inhibitor,
ABT-199 (venetoclax) (21). We found that there was a range of cell killing when combining ABBV-075 with ABT-199 in SCLC cell lines (Fig. 3A). Cell lines that showed strong synergy include NCI-H146, H1963, H345, and NCI-H526 (Fig. 3B). NCI-H146, H1963, and NCI-H526 were also
sensitive to single agent ABBV-075. Interestingly, a few cell lines (such as H345) that were resistant to single agent ABBV-075 were sensitized by the combination treatment with venetoclax. Notably, the majority of the cell lines that demonstrated synergistic effect between ABBV-075 and ABT-199 express BCL2 (Fig. 3C). In Fig. 3D, quantitation of BCL2 protein expression was shown in synergy and no synergy cell lines. There were a few cell lines in which we did not observe synergy despite high BCL2 expression. NCI-H889 cells are known to have high BCL2 amplification and are solely dependent on BCL2 for survival (22), thus the effect of adding BET inhibition is marginal. On the other hand, even though NCI-H211 and DMS53 express BCL2, these lines are very sensitive to single agent ABBV-075 and that could explain the lack of synergy with ABT-199. Other than cell lines that are sensitive to single agent ABBV-075 or

ABT-199, all cell lines that exhibited synergy express BCL2 protein (BCL2 to actin ratio >0.2) while only 1 out of 5 cell lines that exhibited no synergy express BCL2 protein. Nevertheless, our data provide a rationale for treating SCLC with BET and BCL2 inhibitors in cells that express BCL2.

Dependency of SCLC cell lines on BCLxl and BCL2

BIM is usually sequestered by BCLxl and/or BCL2 to prevent cells from undergoing apoptosis. Since ABBV-075 induced the expression of BIM and moderately reduced BCL2 and BCLxl expression, we reasoned that free BIM could be sequestered by BCL2 to avoid cell death. The addition of ABT-199 would thus free BIM from BCL2 and induce cell death. In order to examine this potential mechanism of action for this drug combination, we measured the BCL2- BIM complex upon treatment of ABBV-075 with or without the addition of ABT-199 (Fig. 4A). As shown in Fig. 4B-D, ABBV-075 treatment led to increase of BIM bound to BCL2 in NCI-H146, H1963 and H345 cell lines. Importantly, ABT-199 strongly disrupted BCL2-BIM complexes in all these cells. These results indicate that combination of ABBV-075 and ABT-199 would be more efficacious in inducing apoptosis than single agents alone.

To gain further insight into the sensitivity of SCLC cell lines to ABBV-075 alone and in combination with the BCL2 inhibitor, we determined the dependency of SCLC cell lines to BCLxl and BCL2. Silencing BCL2L1 expression with siRNA led to reduced viability in NCI-H146 and H1963 (Fig. 5), indicating their dependence on BCLxl for survival. Interestingly, the addition of ABT-199 further decreased the viability of these cells. Our data suggested that SCLC cells have a dual dependency on BCLxl and BCL2. Indeed, the majority of SCLC cell lines were sensitive to a BCL2/BCLxl dual inhibitor ABT-263 but not to BCL2-selective inhibitor ABT-199 or BCLxl-selective inhibitor A-1155463 (22).
11

ABBV-075/ABT-199 in vivo efficacy in SCLC models

Based on the in vitro results, we undertook in vivo studies to investigate the efficacy of ABBV-075 in combination with venetoclax. NCI-H146 and H1963 models were chosen since we observed strong combination effect in vitro (Fig. 6A and 6B). While single agent treatment of ABBV-075 or ABT-199 showed marginal efficacy in H1963, tumor regression was observed for the combination during the treatment phase. No obvious toxicity was observed during the treatment period (maximum weight loss for treatment groups was ≤8%). Although the tumors re-grew shortly after the treatment was stopped, they regressed again with re-treatment.
Similarly, single agent activity in NCI-H146 was observed but the combination of ABBV-075 and ABT-199 elicited a more robust effect during the treatment phase. No obvious toxicity was observed during the treatment period.

Collectively, these findings elucidate the mode of action of ABBV-075 in combination with ABT-199 in SCLC. Since SCLC cell line have dual dependence on BCLxl and BCL2, the increase of BIM and moderate decrease in BCL2L1 and BCL2 expression by ABBV-075 together with the BCL2 inhibitor, ABT-199, induce strong apoptosis in these cells (Fig. 6C).

Discussion

We report here that multiple SCLC cell lines are sensitive to BET inhibition by ABBV-075.

Many of the cell lines underwent apoptosis via induction of caspase 3/7. Upregulation of pro- apoptotic protein BIM and downregulation of anti-apoptotic protein BCLxl and BCL2 were observed. In addition, silencing BCL2L11 could rescue sensitive cells from BET inhibition. Synergy

was observed when co-treating BET inhibitor with BCL2 inhibitor venetoclax (ABT-199) in vitro

and in vivo, and in vitro efficacy positively correlated with BCL2 expression.

We found that high percentage of SCLC cell lines underwent apoptosis upon BET inhibitor treatment. High percentage of cellular apoptosis was also detected in AML cell lines (13), and other hematological malignancies (33). We hypothesized that sensitivity of SCLC to BET inhibitor is due to the dependency of SCLC cells to anti-apoptotic proteins such as BCL2 and BCLxl. SCLC is well known to overexpress BCL2 proteins in part due to amplification of BCL2 locus (6). In addition, most SCLC cells express BCLxl and/or MCL1 (5). These anti-apoptotic proteins sequester pro-apoptotic proteins such as BIM to inhibit cell death. We and others have shown that SCLC cells have strong dependency on BCLxl and BCL2 for survival (Fig. 5 and (5)). In particular, SCLC cell lines are sensitive to silencing BCL2L1 in combination with BCL2 inhibitor venetoclax (ABT-199). Others have shown that SCLC cell lines are sensitive to treatment with navitoclax (ABT-263), a dual inhibitor of BCL2 and BCLxl (22). By contrast, other solid tumors were shown to depend mainly on BCLxl and MCL1 but not BCL2 for survival (34). The role of MCL1 in BET inhibitor sensitivity in SCLC cells is currently under investigation. Interestingly, a recent report also revealed that the expression signatures of the apoptotic genes BCL2, BCL2L1, and BAD significantly predict response to BET inhibitor (30), suggesting the apoptotic program as a determinant of response to BET inhibitors.

The sensitivity of SCLC to BET inhibitor(s) has been recently reported (19), and shown to be mediated by downregulation of the neuroendocrine transcription factor ASCL1. We focused on ABBV-075-induced apoptosis and demonstrate that modulation of BIM, BCL2, and BCLxl expression as the key mechanism of action that determines sensitivity and growth inhibition.
The mechanism of BIM induction is unclear but could potentially through FOXO3a post-

transcriptional mechanisms (35). Furthermore, although SCLC tumors and cell lines have MYC, MYCN, MYCL amplifications, association between sensitivity to BET inhibitor and overall MYC status is currently under investigation. Literature review suggests that MYC expression may play a role in leukemia (10, 11), multiple myeloma (9, 12), and hepatocellular carcinoma (27), and MYCN in neuroblastoma (15). However, the role of MYC in SCLC is uncertain. For example, one study shows that MYC does not play a role in response to BET inhibitor JQ1 in SCLC (19) while another study suggests BET inhibitor JQ1 is more active in MYC amplified cell lines (20). In addition, BET inhibition with JQ1 occurs in the absence of modulation of MYC gene expression in aggressive B-cell lymphoma (14). Further experimentation is required to determine the role of MYC status in the response to BET inhibitor.

We showed very strong combination effect between BET inhibitor ABBV-075 and the BCL2 inhibitor venetoclax (ABT-199). This combination was recently shown to be effective in an AML cell line and in primary double hit lymphoma cells (30, 36). We showed that there is an induction of BIM by BET inhibition that could prime cells to apoptosis. In addition, we showed that both BCL2 and BCLxl are moderately reduced and more BIM is sequestered by BCL2 upon BET inhibitor treatment. The subsequent addition of BH3 peptidomimetics would free BIM and induce apoptosis. Similar observations between BCL2 inhibitors with targeted agents that induce BIM were observed by others. For example, EGFR inhibitors are known to induce BIM in NSCLC cells and combination was observed with ABT-737, an analog of navitoclax (37, 38).

Based on these observations, a combination regimen including BET inhibitor and BCL2 inhibition would be highly desirable for treating SCLC cancer. Future studies should investigate the efficacy in patients and the utility of BCL2 expression or amplification as a stratification biomarker.

Acknowledgements

We thank AbbVie members of the BET biology and apoptosis groups for helpful discussion. We thank Joel Leverson, an AbbVie employee, for critical review of the manuscript.

References

1. Witschi H. A short history of lung cancer. Toxicol Sci 2001;64(1):4-6.
2. Bunn PA, Jr., Minna JD, Augustyn A, et al. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? J Thorac Oncol 2016;11(4):453-74.
3. Semenova EA, Nagel R, Berns A. Origins, genetic landscape, and emerging therapies of small cell lung cancer. Genes Dev 2015;29(14):1447-62.
4. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015;524(7563):47-53.
5. Tahir SK, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 2007;67(3):1176-83.
6. Olejniczak ET, Van Sant C, Anderson MG, et al. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 2007;5(4):331-9.
7. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3- only ligands allows complementary apoptotic function. Mol Cell 2005;17(3):393-403.
8. Spigel DR, Socinski MA. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J Thorac Oncol 2013;8(5):587-98.
9. Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146(6):904-17.
10. Dawson MA, Prinjha RK, Dittmann A, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011;478(7370):529-33.
11. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011;478(7370):524-8.
12. Loven J, Hoke HA, Lin CY, et al. Selective inhibition of tumor oncogenes by disruption of super- enhancers. Cell 2013;153(2):320-34.
13. Mertz JA, Conery AR, Bryant BM, et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011;108(40):16669-74.
14. Hogg SJ, Newbold A, Vervoort SJ, et al. BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Mol Cancer Ther 2016;15(9):2030-41.
15. Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov 2013;3(3):308-23.
16. Wang L, Pratt JK, Hasvold L, et al. Bromodomain inhibitors Example 36e. Patent US9296741 B2 2014:47.
17. Faivre EJ, Wilcox D, Lin X, et al. Exploitation of Castration-Resistant Prostate Cancer Transcription Factor Dependencies by the Novel BET Inhibitor ABBV-075. Mol Cancer Res 2017;15(1):35-44.

18. Lin X, Huang X, Uziel T, et al. HEXIM1 as a robust pharmacodynamic marker for monitoring target engagement of BET family bromodomain inhibitors in tumors and surrogate tissues. Mol Cancer Ther 2017.
19. Lenhart R, Kirov S, Desilva H, et al. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression. Mol Cancer Ther 2015;14(10):2167-74.
20. Kaur G, Reinhart RA, Monks A, et al. Bromodomain and hedgehog pathway targets in small cell lung cancer. Cancer Lett 2016;371(2):225-39.
21. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19(2):202-8.
22. Leverson JD, Phillips DC, Mitten MJ, et al. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Sci Transl Med 2015;7(279):279ra40.
23. Sarthy A, Li L, Albert DH, et al. ABBV-075, a novel BET family bromodomain inhibitor, represents a promising therapeutic agent for a broad spectrum of cancer indications. Cancer Res 2016;76(14 Suppl):Abstract nr 4718.
24. Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981;35:269-335.
25. Lam LT, Zhang H, Xue J, Leverson JD, Bhathena A. Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines. Cancer Cell Int 2015;15(1):5.
26. Phillips DC, Xiao Y, Lam LT, et al. Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199). Blood Cancer J 2015;5:e368.
27. Li GQ, Guo WZ, Zhang Y, et al. Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression. Oncotarget 2016;7(3):2462-74.
28. Gallagher SJ, Mijatov B, Gunatilake D, et al. The epigenetic regulator I-BET151 induces BIM- dependent apoptosis and cell cycle arrest of human melanoma cells. J Invest Dermatol 2014;134(11):2795-805.
29. Patel AJ, Liao CP, Chen Z, Liu C, Wang Y, Le LQ. BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction. Cell Rep 2014;6(1):81- 92.
30. Conery AR, Centore RC, Spillane KL, et al. Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response. Cancer Res 2016;76(6):1313-9.
31. Ren D, Tu HC, Kim H, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK- dependent cell death program. Science 2010;330(6009):1390-3.
32. Jiang SX, Sato Y, Kuwao S, Kameya T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J Pathol 1995;177(2):135-8.
33. Ceribelli M, Kelly PN, Shaffer AL, et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014;111(31):11365-70.
34. Lam LT, Zhang H, Chyla B. Biomarkers of Therapeutic Response to BCL2 Antagonists in Cancer. Mol Diagn Ther 2012;16(6):347-56.
35. Heinemann A, Cullinane C, De Paoli-Iseppi R, et al. Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling. Oncotarget 2015;6(25):21507-21.
36. Johnson-Farley N, Veliz J, Bhagavathi S, Bertino JR. ABT-199, a BH3 mimetic that specifically targets Bcl-2, enhances the antitumor activity of chemotherapy, bortezomib and JQ1 in “double hit” lymphoma cells. Leuk Lymphoma 2015;56(7):2146-52.
37. Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics. PLoS Med 2007;4(10):1681-89; discussion 90.
38. Gong Y, Somwar R, Politi K, et al. Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. PLoS Med 2007;4(10):e294.

Figure Legends

Figure 1. SCLC cell lines undergo apoptosis upon BET inhibitor (ABBV-075) treatment. (A) Sensitivity to ABBV-075 across SCLC cell lines. (B) Percent of apoptosis positive cells as determined by Annexin V staining upon 0.3 M ABBV-075 treatment. (C) Correlation between viability / proliferation (IC50) and apoptosis (% Annexin V) induced by ABBV-075 in SCLC cell lines. (D) ABBV-075 induces caspase 3/7 activity in ABBV-075-sensitive SCLC cell lines. Caspase 3/7 activity was evaluated in SCLC cell lines treated with increasing concentration of ABBV-075 for 48 hours. (E) Cell cycle arrest induced by ABBV-075. NCI-H1048 cells were treated with or without ABBV-075 for 48 hours and assayed for the percentage of cells in each phase of the cell cycle.

Figure 2. BET inhibitor modulates expression of BH3 proteins in SCLC cell lines. (A) Effect of BH3 family genes downregulation on survival of ABBV-075 sensitive cells. NCI-H146 and H1963 cells were transfected with control, BIM, BAD, BAX, or BAK siRNA for 24 hours before treatment with 100nM ABBV-075 for additional 48 hours, and viability was assessed. Data shown are representative of three independent experiments. *p<0.05. (B) RNA expression of BH3 family genes. NCI-H146 and H1963 cells were treated with DMSO, 50 or 200 nM ABBV-075 for 6 or 24 hours. RNA expression of BCL2L11, BAD, BAK1 and BAX, was measured by qPCR and normalized to DMSO control. (C) Protein expression of BIM upon treatment with ABBV-075. NCI-H146 and H1963 cell lines were treated with DMSO, 100 nM, or 400nM ABBV-075 for 24 hours. Protein expression was measured by western blotting.

Figure 3. BCL2 expression is predictive of ABBV-075 and ABT-199 combination in SCLC cell lines.

(A) SCLC cell lines were treated with increasing concentrations of ABBV-075 and ABT-199 for 3 days. Viability was determined and combination effect was analyzed with Bliss analysis. Scores greater than 600 were considered strongly synergistic (+++); 400-600 were considered synergistic (++); 250-400 were considered additive (+); and 0-250 were considered no combination effect (-). (B) Representative dose matrices showing combination effect of ABBV- 075 and ABT-199 in H1963, NCI-H146, and H345 cells. (C) Western blot was used to measure expression of BCL2, BCLxl, and MCL1. Actin was used as control. (D) Quantitation of BCL2 protein expression in SCLC cell lines with or without synergy between ABBV-075 and ABT-199. Cell lines with sensitivity to single agent ABBV-075 or ABT-199 were indicated.

Figure 4. ABBV-075 increases the interaction between BCL2 and BIM. (A) Schematic view of the ELISA to detect BCL2-BIM interaction. (B, C, and D) NCI-H146, H1963 and H345 cells were treated with increasing concentration of ABBV-075 and/or ABT-199 for 24 hours, and the BCL2- BIM complex was measured in cell lysates. Data shown are representative of two independent experiments.

Figure 5. Dependencies of SCLC cell lines to BCLxl and BCL2. H1963 and NCI-H146 cells were reverse transfected with control or BCL2L1 (BCLxl) siRNA and treated with increasing concentration of ABT-199 (0-300 nM) for 48 hours. Viability was assessed. Data shown are representative of two independent experiments. Levels of silencing of BCL2L1 was determined by QuantiGene assay (25).

Figure 6. In vivo efficacy of ABBV-075 in combination with ABT-199 in SCLC xenograft models H1963 (A) and NCI-H146 (B). Treatment period was indicated. Weight loss for H1963 groups- vehicle: 5%; venetoclax: 2%; ABBV-075: 3%; and combination: 4%. Weight loss for NCI-H146
groups-vehicle: 0%; venetoclax: 2%; ABBV-075: 8%; and combination: 7%. (C) A model describing the rationale for targeting BET and BCL2 in SCLC cells. BET inhibitor ABBV-075 induces BIM in SCLC cells leading to moderate cell death. BIM binds to BCL2 and “primes” cells to further apoptosis induced by venetoclax (ABT-199) treatment. The combination of BET inhibitor and BCL2 inhibitor induces strong apoptosis in these cells.

A D
10.000

1.000

0.100

0.010

0.001

B 80 E
70
60
50
40
30
20
10
0

C
10

ABBV-075 (nM)
0
16
63
250
1000

0.1

0.01
10 100
Annexin V positive cells (%)

A NCI-H146 H1963
*
*
*

100

*
100

25 25

0
sictrl siBIM siBAD siBAX siBAK
B NCI-H146
2.5

2.0

sictrl siBIM siBAD siBAX siBAK

H1963

BCL2L11
(BIM)

2.0
1.5
1.0
0.5
0.0

1.5
1.0
0.5
0.0

ABBV-075 (nM) DMSO 50 200 DMSO 50 200

DMSO 50 200 DMSO 50 200

BAD

1.5
1.0
0.5
0.0

6 hr 24 hr

1.5
1.0
0.5
0.0

6 hr 24 hr

ABBV-075 (nM) DMSO 50 200 DMSO 50 200
6 hr 24 hr
1.5

1.5

DMSO 50 200 DMSO 50 200
6 hr 24 hr

BAK1

1.0
0.5
0.0

ABBV-075 (nM) DMSO 50 200 DMSO 50 200

DMSO 50 200 DMSO 50 200

BAX

1.5
1.0
0.5
0.0

6 hr 24 hr

1.5
1.0
0.5
0.0

6 hr 24 hr

ABBV-075 (nM) DMSO 50 200 DMSO 50 200
6 hr 24 hr

DMSO 50 200 DMSO 50 200
6 hr 24 hr

H1963 NCI-H146

100

siCtrl siBCLxl

0
0 3.3 11 33 100 300 0 3.3 11 33 100 300
Venetoclax concentration (nM)

125

100

75
siCtrl
50 siBCLxl

0
H1963 NCI-H146

A
2000

1500

1000

500

H1963

vehicle ABT-199
50mg/kg
ABBV-075
0.75 mg/kg
ABT-199
50mg/kg,
ABBV-075
0.75 mg/kg

B
1000

750

500

250

NCI-H146

Vehicle ABT-199
50mg/kg
ABBV-075
0.75 mg/kg
ABT-199
50mg/kg,
ABBV-075
0.75 mg/kg

0 treatment 0
0 7 14 21 28 35 42
Days Post Ini a on of Dosing
C

0 7 14 21
Days Post Ini a on of Dosing

Author Manuscript Published OnlineFirst on May 3, 2017; DOI: 10.1158/1535-7163.MCT-16-0459 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

Vulnerability of small cell lung cancer to apoptosis induced by the combination of BET bromodomain proteins and BCL2 inhibitors
Lloyd T. Lam, Xiaoyu Lin, Emily J. Faivre, et al.
Mol Cancer Ther Published OnlineFirst May 3, 2017.

Updated version

Supplementary
Material
Author Manuscript

Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-16-0459
Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2017/05/03/1535-7163.MCT-16-0459.DC1

Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Reprints and Subscriptions
Permissions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [email protected].

To request permission to re-use all or part of this article, contact the AACR Publications Department at [email protected].